Feature

UK Authorization for Aflibercept  

MHRA clears Eylea for macular edema following retinal vein occlusion

  • By

  • March 3, 2026

  • 2 min

Share

  • 1

    Aflibercept 8 mg approved for retinal vein occlusion (RVO) in the UK.

  • 2

    Suitable for treating visual impairment from RVO.

  • 3

    Approval based on QUASAR trial data.

  • 4

    8 mg group had fewer injections and similar visual outcomes as 2 mg.

  • 5

    Over 60% of patients in 8 mg achieved longer treatment intervals.

  • 6

    Safety profile consistent with previous studies.

  • 7

    Updated posology allows minimum 4-week treatment intervals.

Original Source(s)

UK Authorization for Aflibercept  

MHRA clears Eylea for macular edema following retinal vein occlusion

  • March 3, 2026

  • 2 min

Related Content

Metformin and AMD: Signal or Noise?

Five-year population study details 37% lower incidence of intermediate AMD in type 2 diabetic patients prescribed metformin

Understanding Protocol AO, the DRCR Retina Network’s Study of Home OCT

A conversation with Christina Y. Weng, MD, MBA

Efficacy and Safety of 8 mg Aflibercept in PULSAR Extension

Patients who switched from 2 mg to 8 mg maintained their vision and extended time between treatments with no vasculitis or other retinal occlusive events.